At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos discusses an open-label, multicentre, phase Ib study of the safety, tolerability and dose regimen of the anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in patients with multiple myeloma.
Backbone regimens include bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone.
Advertisement